Search results
Showing 16 to 30 of 154 results for multiple sclerosis
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults.
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)
Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]
In development Reference number: GID-TA11333 Expected publication date: TBC
Natalizumab for treating rapidly evolving severe relapsing–remitting multiple sclerosis (TA127)
Evidence-based recommendations on natalizumab (Tysabri) for treating rapidly evolving severe relapsing–remitting multiple sclerosis in adults.
Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)
Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.
Topic prioritisation
Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]
Topic prioritisation
Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]
Topic prioritisation
Siponimod for treating multiple sclerosis in people 10 to 17 years [TSID12317]
Topic prioritisation